# NCT04970901 (NCT04970901)

> A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04970901
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ADC Therapeutics S.A.
- Conditions: B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions: Loncastuximab Tesirine; Polatuzumab Vedotin; Glofitamab; Mosunetuzumab; Obinutuzumab
- Enrollment: 154
- Primary outcome: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Primary outcome: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
- Primary outcome: Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay
- Primary outcome: Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption
- Primary outcome: Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction
- Primary outcome: Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements
- Primary outcome: Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs
- Primary outcome: Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
- Primary outcome: Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements

## Commentary we found

- YouTube: 8
- Podcasts: 7
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04970901

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04970901", "email": "<work email>"}; the inbox owner confirms by the emailed link.